Amivantamab, CAS 2171511-58-1

Product Description: Amivantamab (JNJ-61186372) is a human EGFR-MET bispecific antibody with immune anticancer activity. Amivantamab inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells[1].

Applications: Cancer-programmed cell death

Formula: N/A

References: [1]Keunchil Park, et al. Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. J Clin Oncol. 2021 Oct 20;39(30):3391-3402. /[2]Jiyeon Yun, et al. Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. Cancer Discov. 2020 Aug;10(8):1194-1209. 

CAS Number: 2171511-58-1

Molecular Weight: N/A

Compound Purity: 99.90

Research Area: Cancer

Solubility: H2O

Target: EGFR

• Artikelnummer: MEXHY-P9977-10
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P9977-10
• Verpackungseinheit: 10 mg
• Mengeneinheit: STK
• Konjugat: Unconjugated